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ABSTRACT
Objective: Conduct an economic evaluation based on
best currently available evidence comparing alternative
treatments levonorgestrel-releasing intrauterine system,
depot-medroxyprogesterone acetate, combined oral
contraceptive pill (COCP) and ‘no treatment’ to prevent
recurrence of endometriosis after conservative surgery
in primary care, and to inform the design of a planned
trial-based economic evaluation.
Methods: We developed a state transition (Markov)
model with a 36-month follow-up. The model structure
was informed by a pragmatic review and clinical
experts. The economic evaluation adopted a UK
National Health Service perspective and was based on
an outcome of incremental cost per quality-adjusted
life year (QALY). As available data were limited,
intentionally wide distributions were assigned around
model inputs, and the average costs and outcome of
the probabilistic sensitivity analyses were reported.
Results: On average, all strategies were more
expensive and generated fewer QALYs compared to no
treatment. However, uncertainty attributing to the
transition probabilities affected the results. Inputs
relating to effectiveness, changes in treatment and the
time at which the change is made were the main
causes of uncertainty, illustrating areas where robust
and specific data collection is required.
Conclusions: There is currently no evidence to
support any treatment being recommended to prevent
the recurrence of endometriosis following conservative
surgery. The study highlights the importance of
developing decision models at the outset of a trial to
identify data requirements to conduct a robust post-
trial analysis.
INTRODUCTION
Endometriosis is a chronic condition where
tissue resembling that of the lining of the
uterus (endometrium) grows in the pelvis
and other areas of the body in response to
ovarian hormones.1 The condition affects
2–10% of women of reproductive age, and it
is suggested that the economic impact of the
condition is similar to other chronic diseases,
such as diabetes mellitus and asthma.2 3 The
predominant complaint in women with
endometriosis is pelvic pain.1 While a reduc-
tion in pain is important to women, it is also
important to assess the impact of treatment
on general well-being and quality of life.1–4
Conservative surgical interventions that pre-
serve fertility, such as laparoscopic removal
or destruction of endometriotic tissue,
are typically used to treat the condition.
However, following surgery, there is an esti-
mated 40–45% risk of symptom recurrence,
increasing the likelihood of repeat surgery or
more radical options such as hysterectomy.5
The underlying mechanisms explaining
recurrence are uncertain. Recurrence may
occur due to the regrowth of residual
endometriotic lesions that were not com-
pletely removed in the surgery, growth of
Strengths and limitations of this study
▪ To our knowledge, this is the first study to
conduct an economic evaluation of hormonal
treatment for endometriosis following conserva-
tive surgery.
▪ The model-based analysis is preliminary but an
integral component of a wider study comprising
a randomised controlled trial.
▪ The limitations relate to the limited data available
to determine which treatment should currently
be recommended for treatment.
▪ Structural assumptions required for the model
were not tested in a sensitivity analysis, as this
would not have improved the precision of our
findings.
▪ It was problematic to synthesise all available evi-
dence for use in the model, so wide distributions
were appropriately assigned to test the extent to
which uncertainty in the parameters alters the
results, and whether a trial is required.
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microscopic endometriosis undetected at surgery, or the
development of de-novo lesions, or a combination of
these. To eliminate or delay recurrence is presently an
unmet medical need in the management of
endometriosis.
In some small trials, hormonal therapy following con-
servative surgery has prevented or delayed recurrence of
endometriosis.6 7 The levonorgestrel-releasing intrauter-
ine device (LNG-IUS) can be inserted during surgery, or
subsequent to surgery by a general practitioner (GP),
and is effective for 5 years. Other options include depot-
medroxyprogesterone acetate (DMPA), an intramuscular
injection that is administered every 3 months, and the
combined oral contraceptive pill (COCP). In the
absence of deﬁnitive clinical trials demonstrating evi-
dence of effectiveness of one over the other, there is
wide variation in their use which is dictated by personal
preference and side effects.7
This study represents the preliminary component of
an NIHR-funded study which includes a randomised
controlled trial (RCT) (PRE-EMPT) (http://www.
controlled-trials.com/ISRCTN97865475). Prior to this
study, the applicants carried out a survey of the British
Gynaecological Endoscopy Society members. The survey,
which was reported in the funding application and the
trial protocol, provided key information which was used
to design the main RCT. It indicated that almost a
quarter of clinicians used no postoperative treatment,
and that the most commonly prescribed treatments are
LNG-IUS, COCP and DMPA. It suggested that oral pro-
gestogens and GnRH analogues are not commonly pre-
scribed. Thus, it was the three treatments of LNG-IUS,
COCP, DMPA and ‘no treatment’ that were deemed
to be the strategies most in need of evaluation.
Furthermore, limiting the trial to just four main compar-
isons allowed a deliverable trial to be designed. The
planned RCT will collect data to explore the most effect-
ive and cost-effective treatment for preventing endomet-
riosis following surgery, but is not due to report for
4 years. To ensure that treatment decisions are based on
robust evidence prior to trial data collection, it is import-
ant to explore key aspects of uncertainty associated with
input parameters that feed into the trial evaluation.
Therefore, a pretrial economic analysis is carried out to
support immediate decisions, explore decision uncer-
tainty and to inform areas of particular focus for data
collection in the full RCT.
The aim of the preliminary component of the study
was to (1) conduct an economic evaluation based on
existing evidence for preventing endometriosis; (2)
inform the design and analysis for the planned full trial-
based economic evaluation.8
METHODS
We carried out a model-based economic evaluation
which compared each hormonal treatment strategy,
LNG-IUS, DMPA, COCP and no treatment in order to
establish the most cost-effective approach for reducing
symptom recurrence following conservative surgery for
endometriosis based on the existing available evidence
prior to the planned RCT. The evaluation took the form
of a cost-utility analysis, based on an outcome of cost per
quality-adjusted life year (QALY). A UK National Health
Service perspective in a primary care setting was used.
The analysis provides an assessment of the difference in
costs and outcomes in terms of QALYs between the
potential interventions over a 36-month time horizon.
The time horizon reﬂects that of the relevant treatments
that are required post-surgery and the need for treat-
ment will be clear within that time period, it is also the
time period on which the planned full RCT will be
based.
Model
We developed a state transition (Markov) model in
Microsoft Excel. The model structure was based on
the NIHR-funded (PRE-EMPT study) RCT design,
which was informed by a review of existing evidence
and clinical input (http://www.controlled-trials.com/
ISRCTN97865475). The model structure was reﬁned by
iterative discussion with expert clinical colleagues. The
initial structure was discussed with all clinicians associated
with the planned RCT, disagreement was resolved by com-
promise, as practice varies considerably, and the ﬁnal struc-
ture represents the most pragmatic structure which
achieved consensus. Based on the results of our survey
which informed the design of the planned RCT, we com-
pared the same four alternative treatment strategies follow-
ing conservative surgery: (1) no treatment, (2) LNG-IUS,
(3) DMPA and (4) COCP. Where the ﬁrst active treatment
is deemed not effective, the patient is assumed to receive
an additional round of hormonal treatment prior to
having further surgery. Thus, as these treatments are not
mutually exclusive, the pathway for each strategy is deﬁned
by the intervention that is tried ﬁrst. Figure 1 shows the
clinical pathway for the alternative treatment strategies. A
monthly time cycle was used, as this was deemed to appro-
priately reﬂect changes in outcomes and resource use. We
compared a cohort of 1000 women for each treatment
strategy. The starting age was 32 years, based on the
average age of a woman who has undergone conservative
surgery for endometriosis.9 All-cause mortality was not
considered due to the relatively short time horizon of the
pretrial model. A half-cycle correction was not employed
because transitions are deemed to occur at the end of the
cycle as we are using a discrete model not a continuous
model, therefore the use of the half-cycle correction
would be incorrect. The following assumptions were made
and developed based on clinical expertise from the
PRE-EMPT trial research group. In developing the
assumption, the group was careful to consider variation in
practice which was likely to exist to ensure the assumptions
were justiﬁed given potential variation. All assumptions
were agreed prior to conducting the analysis.
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Model assumptions
▸ If a woman is symptomatic, and LNG-IUS is the initial
treatment, the device will remain in situ for at least
12 months before it can be removed. We use the
maximum amount of time suggested by clinicians for
each treatment, to ensure the analysis was not favour-
ing any particular treatment. It is assumed that
LNG-IUS is inserted after surgical treatment for
endometriosis
▸ If a woman is asymptomatic with LNG-IUS, the device
is not removed for the remainder of the analysis
▸ If a woman is asymptomatic while receiving treatment
with either COCP or DMPA, the treatment will not be
stopped for at least 6 months. Following these
6 months, the woman can stop treatment, and it is
assumed that the woman will remain asymptomatic
without further treatment
▸ If symptomatic once off treatment, the woman will
remain in this symptomatic state for 6 months before
recommencing treatment or spontaneously becoming
asymptomatic while off treatment. This enables sufﬁ-
cient time for previous hormonal effects to subside
and time to determine if symptoms adjust or are
resolved
▸ The second hormonal treatment will comprise one of
the two remaining treatment strategies or GnRHa,
which includes hormone replacement therapy, to
enable the treatment to be used longer term than
6 months
▸ If symptomatic on the second hormonal treatment,
the woman cannot have surgery until after 6 months
have passed
▸ If asymptomatic on the second hormonal treatment,
the woman will not stop treatment and will remain
asymptomatic for at least 6 months
▸ A woman will undergo two sets of hormonal treat-
ment before she can have either conservative surgery
or hysterectomy
Figure 1 Clinical pathways for ‘no treatment’ and hormonal treatment (*For ‘hormonal’ the treatment could be GnRHa or Mirena
or COCP (33.3% chance of each)—see assumptions. The pathway for hormonal treatment with GnRHa will be the same as the
pathway in the hormonal treatment model). COCP, combined oral contraceptive pill; GnRHa, gonadotropin-releasing hormone
analogue; LNG-IUS, levonorgestrel-releasing intrauterine device.
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▸ The impact of any of the treatments on long-term fer-
tility has not been considered in the model
A pragmatic literature search was carried out to identify
evidence on the effectiveness of the four treatment strat-
egies to inform parameter inputs and their distributions
for the transition probabilities of the decision model.
Thus, the evidence on current medical therapies
described in the PRE-EMPT trial funding application
and protocol was reviewed to identify data on effective-
ness required for the transition probability parameters in
the model. To identify literature for the utility values for
the health states in the model, we searched the Web of
Science database using the following key words ‘endo-
metriosis’ and ‘economic’ and ‘EQ-5D’ or ‘quality of life’
or ‘SF-6D’. A few small studies were identiﬁed that
assessed the effectiveness of one of the treatment strat-
egies, COCP, DMPA or LNG-IUS.10–14 Treatment effect-
iveness was typically measured in relation to pain and was
captured using either the visual analogue scale (which
provides a measure of quality of life), endometriosis-
speciﬁc scale or the percentage improvement in a spe-
ciﬁc category. However, the available data were all based
on small studies which used different measures for effect-
iveness, and so, synthesis into a meaningful analysis
proved problematic. Additionally, data on disease recur-
rence after conservative surgery were extremely dispar-
ate. As a consequence of limited data availability in the
published literature, transition probabilities were
assigned by asking two of the trial clinicians to rank the
likelihood of each subsequent event occurring from 1 to
5 or 1 to 3, and distributions were assigned around these
rankings to assess, as far as feasible, any uncertainty asso-
ciated with the given values. These data are presented in
table 1. The intention was to assign distributions around
the estimates which were deliberately wide to identify the
extent to which changes in these values gave a different
cost-effectiveness decision (outlined later) as is com-
monly the case for pretrial analyses where the purpose is
to determine whether additional information is required
to conduct a more robust analysis.15
Utilities
A search of the relevant literature did not identify any
evidence on the effectiveness of the treatments in terms
Table 1 Probability parameters used in the analysis
Probability parameters Distribution Parameters
LNG-IUS
LNG-IUS to asymptomatic on LNG-IUS β (3,2)
LNG-IUS to symptomatic on LNG-IUS β (3,2)
Remain asymptomatic on LNG-IUS Fixed 1
Remain asymptomatic off treatment Fixed 1
Remain symptomatic on LNG-IUS (<12 months) Fixed 1
Remain symptomatic on LNG-IUS (>12 months) Dirichlet 8
Symptomatic with LNG-IUS to symptomatic off treatment 20
Symptomatic with LNG-IUS to change treatment (hormonal) 16
Symptomatic with LNG-IUS to hysterectomy 4
Symptomatic with LNG-IUS to conservative surgery 2
Remain symptomatic off treatment (<6 months) Fixed 1
Remain symptomatic off treatment (>6 months) Dirichlet 6
Symptomatic off treatment to asymptomatic off treatment 2
Symptomatic off treatment to change treatment (hormonal) 10
Change treatment (hormonal) to asymptomatic on 2nd treatment β (3,2)
Change treatment (hormonal) to symptomatic on 2nd treatment β (3,2)
Remain asymptomatic on 2nd treatment (<6 months) 1 Fixed
Remain asymptomatic on 2nd treatment (>6 months) β (3,2)
Asymptomatic on 2nd treatment to asymptomatic off treatment β (3,2)
Remain symptomatic on 2nd treatment (<6 months) Fixed 1
Remain symptomatic on 2nd treatment (>6 months) Dirichlet 6
Symptomatic on 2nd treatment to 2nd conservative surgery 10
Symptomatic on 2nd treatment to hysterectomy 2
2nd conservative surgery to symptomatic post-conservative surgery β (3,2)
2nd conservative surgery to asymptomatic post-conservative surgery β (3,2)
Remain symptomatic post-conservative surgery Fixed 1
Remain asymptomatic post-conservative surgery Fixed 1
Hysterectomy to symptomatic post-hysterectomy β (3,2)
Hysterectomy to asymptomatic post-hysterectomy β (3,2)
Remain symptomatic post-hysterectomy Fixed 1
Remain asymptomatic post-hysterectomy Fixed 1
The same principle applies to the transitions for other treatments.
LNG-IUS, levonorgestrel-releasing intrauterine device.
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of utilities (which is a measure of preference for alterna-
tive health states) as measured by generic health-related
quality of life instruments (ie, EQ-5D/ SF-6D) on which
to base distributions. As a result of the dearth of evi-
dence, clinicians were asked to rank the health states on
a 0–10 scale for the utilities associated with the treat-
ments for endometriosis. The 0–10 scale is analogous to
the 0–1 utility scale, and is thought to be easier to com-
prehend when providing estimates, so we used 0–10 as a
more pragmatic method for generating utilities. Similar
to the transition probabilities and for the same reasons,
an intentionally broad distribution was then assigned
around these assumed point estimates with values in a
range of 0.05 above and below. Where the clinicians dis-
agreed with a given utility value, the range around the
point estimate was broadened to account for this.
Table 2 shows the estimated point estimates, the range
used and the associated distribution to assess uncertainty
around the given estimate.
Cost and resource use
The costs for all treatment strategies include healthcare
staff costs and the cost of the intervention (table 3). The
estimates for resource use were taken from a recent par-
allel primary study exploring the treatment for a related
condition.16 Thus, LNG-IUS is estimated to take 20 min
to ﬁt, requires disposable items and both a GP and
nurse to be present. Follow-up consultations for treat-
ment with the GP are assumed to last 10 min. Staff costs
were calculated using nationally recognised reference
costs.17 The costs of the treatments were estimated from
the British National Formulary.18 Cost data on hysterec-
tomy and second conservative surgery were taken from
the literature and inﬂated to 2013 prices.19 As recom-
mended by the National Institute for Health and Care
Excellence, a discount rate of 3.5% was applied to both
costs and utilities as the model time horizon is beyond
1 year.20 All costs are reported in 2013 prices in UK (£),
using the UK hospital and community health services
index.17 As the second hormonal treatment can be one
of three treatments, 1/3 of the average unit costs of
three treatments are applied.
Analysis
In the analyses, we compared all four treatment strat-
egies. Dominance is said to occur where a treatment is
both less costly and more effective (ie, produces more
QALYs) than another treatment. For each model input
parameter (ie, effectiveness value, quality of life or utility
value), a wide distribution is assigned to assess the
extent of uncertainty associated with model inputs, and
a value for each parameter is randomly drawn from the
assigned distribution. This process, known as a probabil-
istic sensitivity analysis (PSA), simultaneously changes all
relevant parameters in the model and is repeated 1000
times. To report an overall cost-effectiveness decision,
the uncertainty around the input parameters was sum-
marised as average costs and QALYs.
The 1000 values representing the ranges of incremen-
tal cost and QALYs for one treatment compared to
Table 2 Utility values used in analysis
Health state Estimate* Range Distribution† Source
All pathways
Baseline 0.4 0.35–0.45 β (2,2) Symptomatic off treatment
Asymptomatic off treatment 1 – – Ranking exercise
Symptomatic off treatment 0.4 0.35–0.45 β (2,2) Ranking exercise
Conservative surgery – – – post-surgery
Symptomatic post-conservative surgery 0.35 0.25–0.45 β (2,2) Ranking exercise
Asymptomatic post-conservative surgery 0.8 0.75–0.85 β (2,2) Ranking exercise
Hysterectomy – – – post-surgery
Symptomatic post-hysterectomy 0.25 0.15–0.35 β (2,2) Ranking exercise
Asymptomatic post-hysterectomy 0.7 0.65–0.75 β (2,2) Ranking exercise
DMPA/COCP
Asymptomatic initial treatment 0.7 0.65–0.75 β (2,2) Ranking exercise
Symptomatic initial treatment 0.35 0.25–0.45 β (2,2) Ranking exercise
Change treatment (second treatment) – – – Symptomatic second treatment
Asymptomatic second treatment 0.7 0.65–0.75 β (2,2) Ranking exercise
Symptomatic second treatment 0.25 0.15–0.35 β (2,2) Ranking exercise
LNG-IUS/no treatment
Asymptomatic on LNG-IUS 0.8 0.75–0.85 β (2,2) Ranking exercise
Symptomatic on LNG-IUS 0.35 0.25–0.45 β (2,2) Ranking exercise
Change treatment – – – Symptomatic second treatment
Asymptomatic second treatment 0.7 0.65–0.75 β (2,2) Ranking exercise
Symptomatic second treatment 0.3 0.25–0.35 β (2,2) Ranking exercise
*The estimate reflects the values provided by clinicians and is used only to set the range of values for the analysis.
†These β distributions are applied within the ranges shown in the previous column, not across the full range of possible values from 0 to
1. Thus, the sampled value for any asymptomatic state will always be higher than the sampled value for the corresponding symptomatic state.
COCP, combined oral contraceptive pill; DMPA, depot-medroxyprogesterone acetate; LNG-IUS, levonorgestrel-releasing intrauterine device.
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another are presented on the cost-effectiveness plane
scatter plot to illustrate the distribution of values. These
were used to construct a cost-effectiveness acceptability
curve (CEAC) which shows the probability of each treat-
ment being more cost-effective than the other, across a
range of monetary values that decision-makers may be
willing to pay for an additional QALY. We carried out a
number of bilateral comparisons of treatment strategies,
and therefore, generated several incremental cost-
effectiveness planes and CEACs.
The degree of uncertainty attributable to each param-
eter, that is, transition probability or utilities, was
assessed by ﬁrst holding the transition probabilities con-
stant and allowing for variation around the utilities
alone, and then second, by holding utilities constant
and allowing for variation around the transition prob-
abilities alone. This analysis was carried out by ﬁxing
parameters (ie, transition probabilities) to the last values
that were obtained from a random draw of the distribu-
tion and allowing the parameters for the utilities to be
randomly sampled from the assigned distribution and
vice versa. Cost-effectiveness planes produced for each
set of parameters varied, but it is inappropriate to use all
these planes to produce CEACs, as they will not show
the overall uncertainty. CEACs were only produced to
illustrate the overall uncertainty.
RESULTS
The average costs and QALYs over the 1000 PSA itera-
tions show that LNG-IUS is the most expensive
intervention (£650.94) followed by DMPA (£622.56),
then COCP (£599.93). No treatment is the least expen-
sive intervention (£371.34), and also generated the
greatest number of QALYs (2.27) followed by DMPA and
COCP which both generated 1.92 QALYs, and LNG-IUS
produced the least QALYs at 1.88.
The results show that no treatment dominates all
other treatment strategies as it is both less costly and
based on current evidence generates more QALYs. It
can be seen from the scatter plots and the CEACs
(ﬁgure 2, parts 1–3) that when compared with one
another, there is little difference between the probability
of each of the treatment strategies being cost-effective.
There is clear uncertainty about which of the active
treatment strategies are optimal. When the strategies are
compared with no treatment, no treatment has a greater
probability of being cost-effective at least 80% for all
threshold willingness-to-pay values. The cost-effectiveness
plane which illustrates the incremental costs and QALYs
between the pairs of treatments shows that for every
bilateral comparison of treatment strategies a negative
slope is generated which crosses the origin indicating
that there is considerable uncertainty around the ﬁnd-
ings. Table 4 presents a summary of the average results
obtained from the PSA.
When utilities are held constant and variation is
applied to the transition probabilities incremental costs,
and QALYs again generate a negative slope on the cost-
effectiveness plane (ﬁgure 3, parts 1 and 2) which
crosses the origin in every case, indicating a strong nega-
tive correlation between costs and QALYs, that is, the
Table 3 Cost and resource use data used in analysis
Unit cost (£) Source
LNG-IUS
Consultation (GP 10 min) 26.67 Curtis17/Sanghera et al16
Insertion
GP (20 min) 53.33 Curtis17/Sanghera et al16
Practice nurse (20 min) 17.00 Curtis17/Sanghera et al16
Device cost 88.00 BNF 66
Sterile pack (insertion) 21.63 NICE (inflated to 2011)
Discontinuation
GP (10 min) 26.67 Curtis17/Sanghera et al16
Practice nurse (10 min) 8.50 Curtis17/Sanghera et al16
Sterile pack (removal) 3.77 NICE (inflated to 2013)
Follow-up
6 weeks review: (GP 10 min) 26.67 Curtis17/Sanghera et al16
3 months: (GP 10 min) 26.67 Curtis17/Sanghera et al16
Combined oral contraceptive (microgynon) 2.82 BNF 66
Consultation: (GP 10 min) 26.67 Curtis17/Sanghera et al16
3 or 6 months review (GP 10 min) 26.67 Curtis17/Sanghera et al16
Methoxyprogesterone acetate injections (Depo-provera) 6.01 BNF 66
Consultation: (GP 10 min) 26.67 Curtis17/Sanghera et al16
3 or 6 months review (GP 10 min) 26.67 Curtis17/Sanghera et al16
Discontinuation (GP 10 min) 26.67 Curtis17/Sanghera et al16
Second conservative surgery 1392.63 Roberts et al19 (inflated to 2013)
Hysterectomy 2432.04 Roberts et al19 (inflated to 2013)
GP, general practitioner; LNG-IUS, levonorgestrel-releasing intrauterine device; NICE, National Institute for Health and Care Excellence.
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treatment could either be more costly and less effective,
or more effective and less costly. Since costs are held
constant, the most likely cause for this slope across the
northwest and southeast quadrants of the cost-
effectiveness plane is the uncertainty around the
transition probabilities. Therefore, inputs relating to
effectiveness, changes in treatment and the time at
which the change is made were the main causes of
uncertainty, illustrating areas where robust and speciﬁc
data collection is required.
Figure 2 Illustrative results for
average 1000 PSA iterations on
the cost-effectiveness plane and
the cost-effectiveness
acceptability curve. COCP,
combined oral contraceptive pill;
DMPA, depot-
medroxyprogesterone acetate;
ICER, incremental cost-
effectiveness ratio; LNG-IUS,
levonorgestrel-releasing
intrauterine device; QALY,
quality-adjusted life year.
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When transition probabilities are held constant and
variation is applied around utilities (ﬁgure 4, parts 1
and 2), it can be seen that relative to the other treat-
ments, the uncertainty is greatest around the quality of
life values for LNG-IUS. In all the bilateral comparisons
including LNG-IUS (LNG-IUS/DMPA, no treatment/
LNG-IUS and COCP/LNG-IUS) the scatter of incremen-
tal costs and QALYs cross the axis of the cost-
effectiveness plane to varying degrees, indicating that
there is uncertainty around the most cost-effective treat-
ment in the comparisons.
DISCUSSION
Main findings
The main ﬁndings from this study are that there is con-
siderable uncertainty about the cost-effectiveness of the
existing treatments to prevent endometriosis following
conservative surgery. The model-based analysis, based on
best available current data, suggests that no treatment is
the appropriate course of action to prevent recurrence
of endometriosis following conservative surgery when
compared with other treatment strategies (DMPA,
COCP and LNG-IUS). This result appears to be driven
by the assumption that being on treatment will itself
lead to a substantial reduction in quality of life. There is
little difference between the probability of all existing
treatment strategies (DMPA, COCP, LNG-IUS) being the
most cost-effective, and none can yet be singled out as a
potential clear contender. In terms of the direction of
results, COCP had the greatest probability of being cost-
effective when compared with DMPA and LNG-IUS.
DMPA had the highest probability of being cost effective
when compared with LNG-IUS.
While no treatment should be recommended at the
current time for this clinical condition, the transition
probabilities, which relate to the effectiveness of the
Table 4 Illustrative results averaged over 1000 PSA
iterations
Mean cost (£) Mean QALY
DMPA 622.56 1.92 Dominated
LNG-IUS 650.94 1.88 Dominated
COCP 599.93 1.92 Dominated
No treatment 371.34 2.27
COCP, combined oral contraceptive pill; DMPA,
depot-medroxyprogesterone acetate; LNG-IUS,
levonorgestrel-releasing intrauterine device; PSA, probabilistic
sensitivity analysis.
Figure 3 PSA results on the cost-effectiveness plane where only transition probabilities are probabilistic. COCP, combined oral
contraceptive pill; DMPA, depot-medroxyprogesterone acetate; LNG-IUS, levonorgestrel-releasing intrauterine device; QALY,
quality-adjusted life year.
8 Sanghera S, et al. BMJ Open 2016;6:e010580. doi:10.1136/bmjopen-2015-010580
Open Access
group.bmj.com on April 20, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
treatment, are subject to a great deal of uncertainty,
which is reﬂected in the results. This wholly supports the
need for further primary research to allow a more con-
clusive recommendation to be made. The full planned
trial is necessary to resolve the uncertainty. The study
highlights the importance of developing decision
models at the outset of a trial to identify data require-
ments to conduct a robust post-trial analysis. Areas in
which the trial should focus data collection are on the
effectiveness of LNG-IUS for this condition, the quality
of life impact of the treatments, and the type and timing
of treatment changes.
Strengths and limitations
We identiﬁed no other economic evaluations that assess
the cost-effectiveness of these treatment strategies for
postsurgical treatment of endometriosis. To our knowl-
edge, this is the ﬁrst study to conduct an economic
evaluation of hormonal treatment for endometriosis fol-
lowing conservative surgery. The model-based analysis
reported here is preliminary but an integral component
of a wider study comprising an RCT. The current ana-
lysis is the ﬁrst to identify and highlight issues that
can be addressed and data that need to be collected in
the trial to enhance the robustness of the trial-based
cost-effectiveness analysis, and will aid the development
of the model structure for the subsequent analysis.
The limitations of this model were that there were no
reliable data available to determine which treatment
should currently be recommended for treatment. Also,
structural assumptions required for the model, such as
allowing women to have three courses of hormonal
treatment prior to surgery rather than two, were not
tested in a sensitivity analysis, as this analysis would not
have improved the precision of our ﬁndings but will be
appropriate for the economic evaluation alongside the
trial. However, these are not limitations that impact on a
purpose of the pretrial analysis to inform data collection.
Further, the data for the transition probabilities found in
the literature were based on small studies, and the
results were based on different measures. Thus, it was
problematic to synthesise this evidence for use in the
model. Wide distributions were appropriately assigned to
test the extent to which uncertainty in the parameters
alters the results and whether a trial is required.
Illustrative data were used: given that the impact of the
treatment on this particular condition is subjective, wide
distributions around values seemed most suitable. Owing
to the pragmatic approach to searching the literature, it
is possible that additional usable studies could be found
Figure 4 PSA results on the cost-effectiveness plane where only utilities are probabilistic. COCP, combined oral contraceptive
pill; DMPA, depot-medroxyprogesterone acetate; LNG-IUS, levonorgestrel-releasing intrauterine device; QALY, quality-adjusted
life year.
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from a comprehensive systematic review. While it is
unlikely a systematic review would reveal enough add-
itional information to have a much higher level of conﬁ-
dence on parameter values, it cannot be ruled out.
CONCLUSION
As there is clear uncertainty around the ﬁndings, it is
important to ensure the most robust evidence on the
effectiveness of these three treatment strategies for
endometriosis is acquired. In the meantime, until the
trial results or other new evidence emerges, no treat-
ment is recommended for the clinical condition follow-
ing conservative surgery. As data are lacking on the
effectiveness of these treatments for endometriosis it
would be beneﬁcial to compare the three treatment
strategies compared in this analysis with a no treatment
strategy as four different arms of the trial. The ﬁndings
also suggest that it is essential to generate reliable
evidence on the effectiveness of LNG-IUS for this condi-
tion, as the uncertainty around the utility, or quality of
life values, has shown to generate both positive and
negative incremental QALYs. In all cases, it is important
to determine how best to capture quality of life data,
and to identify which measure appropriately captures
patient preferences. In addition to the typical data that
are captured as part of the trial, it will be important to
focus data collection to clarify speciﬁcally the type of
treatment change made, if any, and the time (in
months) at which the treatment change occurred. Such
data should include whether and when the patient
stopped treatment. It is also likely that the trial time
horizon may need to be longer than 3 years for the full
beneﬁt of treatments to be seen.
This study suggests that at the current time there is no
evidence to support any treatment being offered for this
condition. However, the study illustrates the beneﬁts and
importance of conducting a model-based economic
evaluation based on available evidence prior to a trial-
based economic evaluation being carried out.8 The
model-based economic evaluation provides information
on areas where speciﬁc and reliable data collection is
required to improve the robustness of the economic
evaluation.
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